Sign in
Taking people in United StatesPhase 1/2

Early safety study of ACCG-2671 in healthy adults and adults with obesity

Tests the safety of ACCG-2671 pills in healthy adults and people with obesity.

Key facts

Who runs it
Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics
Where
Cypress, Decatur, Dilworth, Lake Forest, Springfield, and Webster, United StatesSee the 6 sites
Trial code
Registry title
First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671
Status
Recruiting
Phase
Phase 1/2
People taking part
164 people, planned
Started
29 Dec 2025
Expected to end
Apr 2027
Type of study
Interventional, 5 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • ACCG-2671
  • Placebo
Record updated
14 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults, men and women, to test a new oral drug, ACCG-2671. Parts 1 and 2 enroll healthy people. Part 3 enrolls people with obesity who already take an injectable GLP-1RA.

Age
Parts 1 and 2: 25 to 65 years. Part 3: 25 to 75 years.
Sex
Men and women can join.
Disease stage
Parts 1 and 2: healthy, BMI from 18.0 kg/m2 to under 30.0 kg/m2. Part 3: obesity, BMI 30.0 kg/m2 or higher. Body weight at least 50.0 kg (110 lb).
Earlier treatment
Part 3: must have taken a stable dose of an injectable GLP-1RA for at least 3 months, with stable body weight and no ongoing GLP-1RA-related symptoms or side effects. Dose must not change during the study. Other medicines and supplements are not allowed within 10 days before the first dose or throughout the study.

Main reasons for not taking part

  • Significant heart, lung, liver, kidney, blood, stomach and gut, hormone, immune, skin, mental health or nerve disease
  • Acute illness or major surgery within the past 3 months
  • Clinically significant abnormal lab results
  • Use of prescription or over-the-counter medicines, herbal products, diet aids, vitamins or hormone supplements within 10 days before the first dose
  • Parts 1 and 2: any clinically significant medical condition

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Signed informed consent
  • Men and women with the following at the time of Screening for Part 1 and 2: ≥25 years and ≤65 years of age and BMI ≥18.0 kg/m2 and <30.0 kg/m2
  • For Part 3, ≥25 years and ≤75 years of age and BMI ≥30.0 kg/m2
  • For Part 3, receiving a stable dose of an injectable GLP-1RA for ≥3 months, who responded to GLP1RA treatment with stable body weight and no ongoing GLP-1RA-related symptoms or AEs. For the duration of the study, participants must not be planning to change GLP-1RA dose or discontinue GLP-1RA treatment
  • Body weight ≥50.0 kg at time of screening

Who cannot take part

  • For Parts 1, 2 and 3: participants will be excluded from this study if there is evidence of ANY of the exclusion criteria at the Screening Visit or prior to first dose administration
  • Use of any prescription or over-the counter-medication including herbal products, diet aids, vitamins, or hormone supplements (including contraceptives) within 10 days or 5 times the apparent elimination half-life of the medication (whichever is longer) before the first study drug administration and throughout the study. Exceptions include injectable GLP-1RA treatment for Part 3, Cohort 2c only and medications used to manage AEs at the discretion of an investigator after consultation with the Sponsor
  • For Parts 1 and Part 2: Participants with any clinically significant medical conditions are excluded from the study
  • History or presence of significant CV, pulmonary, hepatic, renal, hematological, GI, endocrine, immunologic, dermatologic, psychiatric, or neurological disease, including any acute illness or major surgery within the past 3 months, or any clinical laboratory abnormality determined by the Investigator to be clinically significant

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 25 and 75 years old?

Where in United States

  • Cypress, TexasHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Decatur, IllinoisHospital not named in the registryContact: Principal InvestigatorNot yet recruiting
  • Dilworth, MinnesotaHospital not named in the registryContact: Principal InvestigatorTaking people
  • Lake Forest, CaliforniaHospital not named in the registryContact: Medical DirectorTaking people
  • Springfield, MissouriHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Webster, TexasHospital not named in the registryContact: Medical DirectorTaking people

About the trial

What the trial wants to find out

This first-in-human study will evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of ACCG-2671. It will also evaluate the effect of food on the pharmacokinetics, safety, and tolerability of a single dose. Parts 1 and 2 will enroll healthy participants, and Part 3 will enroll otherwise healthy participants with obesity.

The 5 groups in the trial

  • Part 1 (SAD)Treatment being tested

    Ascending doses of ACCG-2671 administered orally in healthy participants

    Treatment: ACCG-2671

  • Placebo Part 1 (SAD)Placebo, for comparison

    Administered orally in healthy participants

    Treatment: Placebo

  • Part 2 (Food-effect)Treatment being tested

    Single low dose of ACCG-2671 administered orally in healthy participants under fasted and fed state

    Treatment: ACCG-2671

  • ACCG-2671 Part 3 (MAD)Treatment being tested

    Escalating doses of ACCG-2671 administered orally for 84 days in participants living with obesity (BMI≥30 kg/m2)

    Treatment: ACCG-2671

  • Placebo Part 3 (MAD)Placebo, for comparison

    Placebo administered orally for 84 days in participants living with obesity (BMI≥30 kg/m2)

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food-effect of ACCG-2671
Plain-language title
Early safety study of ACCG-2671 in healthy adults and adults with obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Fit questions
Built from NCT07815678, who can take part
Record updated
14 September 2026